Skip to content

Released Feb 25, 2021, after the close

10-K filed Feb 25, 2021, 56 days after period end · 0001564590-21-008878

Q4 2020 · 10-K
Revenue$1.04M−78.2% vs Q4 2019−97.0% vs Q3 2020
Net Income-$39.42MN/M vs Q4 2019N/M vs Q3 2020
EPS Diluted-$1.11N/M vs Q4 2019N/M vs Q3 2020
Operating Incomederived-$39,642,000N/M
Operating Cash Flowderived-$25,269,000N/M
Free Cash Flowderived-$25,269,000N/M
Margins · derived
Operating margin-3822.8%−3221.0 pt vs Q4 2019
Net margin-3801.2%−3233.0 pt vs Q4 2019

What the release said

The release

Same quarter

MetricQ4 2020Q4 2019Q4 2018Q4 2017
Revenue$1.04M$4.77M$3.74M$3.32M
Net Income-$39.42M-$27.08M-$26.16M-$3.01M
EPS Diluted-$1.11-$0.99-$1.03-$160.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR